Rational Management of Metastatic Castration-Resistant Prostate Cancer: Treatment Insights and Options
Experts discussed various treatment options for a 60-year-old patient with mCRPC, including switching to Lutetium therapy after progression on Apalutamide. Genetic testing, avoiding back-to-back hormonal therapies, and considering novel AR-blockers like Lutetium-PSMA and PARP inhibitors were highlig
0 views • 6 slides